

Chiara Bardella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6118628/publications.pdf>

Version: 2024-02-01

19
papers

1,698
citations

471509

17
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

3915
citing authors

#	ARTICLE	IF	CITATIONS
1	SDH mutations in cancer. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2011, 1807, 1432-1443.	1.0	327
2	Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. <i>Journal of Pathology</i> , 2011, 225, 4-11.	4.5	225
3	Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche. <i>Nature Medicine</i> , 2015, 21, 62-70.	30.7	213
4	Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. <i>Nature Genetics</i> , 2012, 44, 420-425.	21.4	148
5	Expression of Idh1R132H in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis. <i>Cancer Cell</i> , 2016, 30, 578-594.	16.8	122
6	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. <i>Nature Communications</i> , 2015, 6, 6336.	12.8	100
7	Truncated RON Tyrosine Kinase Drives Tumor Cell Progression and Abrogates Cell-Cell Adhesion Through E-Cadherin Transcriptional Repression. <i>Cancer Research</i> , 2004, 64, 5154-5161.	0.9	96
8	Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma. <i>PLoS ONE</i> , 2011, 6, e19868.	2.5	71
9	Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis. <i>Cell Reports</i> , 2018, 22, 3107-3114.	6.4	64
10	Expression Profiling in Progressive Stages of Fumarate-Hydratase Deficiency: The Contribution of Metabolic Changes to Tumorigenesis. <i>Cancer Research</i> , 2010, 70, 9153-9165.	0.9	63
11	IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. <i>Future Oncology</i> , 2013, 9, 1923-1935.	2.4	53
12	ER1± as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7420-7425.	7.1	43
13	p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. <i>International Journal of Cancer</i> , 2006, 118, 2981-2990.	5.1	38
14	Bone morphogenetic protein and Notch signalling crosstalk in poor-prognosis, mesenchymal-subtype colorectal cancer. <i>Journal of Pathology</i> , 2017, 242, 178-192.	4.5	36
15	The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo. <i>Clinical Cancer Research</i> , 2007, 13, 2191-2198.	7.0	29
16	Cells Lacking the Fumarase Tumor Suppressor Are Protected from Apoptosis through a Hypoxia-Inducible Factor-Independent, AMPK-Dependent Mechanism. <i>Molecular and Cellular Biology</i> , 2012, 32, 3081-3094.	2.3	29
17	Serum- and Glucocorticoid-induced Kinase Sgk1 Directly Promotes the Differentiation of Colorectal Cancer Cells and Restrains Metastasis. <i>Clinical Cancer Research</i> , 2019, 25, 629-640.	7.0	28
18	Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. <i>FASEB Journal</i> , 2010, 24, 2680-2688.	0.5	12

#	ARTICLE	IF	CITATIONS
19	HOT mutation screening in human glioblastomas. Future Science OA, 2015, 1, .	1.9	1